PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

  1. Rincón, R.
  2. Cristóbal, I.
  3. Zazo, S.
  4. Arpí, O.
  5. Menéndez, S.
  6. Manso, R.
  7. Lluch, A.
  8. Eroles, P.
  9. Rovira, A.
  10. Albanell, J.
  11. García-Foncillas, J.
  12. Madoz-Gúrpide, J.
  13. Rojo, F.
Revue:
Oncotarget

ISSN: 1949-2553

Année de publication: 2015

Volumen: 6

Número: 6

Pages: 4299-4314

Type: Article

DOI: 10.18632/ONCOTARGET.3012 GOOGLE SCHOLAR lock_openAccès ouvert editor